Kyoto-iCAP — Kyoto University Innovation Capital

Kyoto University Innovation Capital (Kyoto-iCAP), established in December 2014 as a wholly owned Kyoto University subsidiary certified under Japan's Industrial Competitiveness Enhancement Act, is a university-affiliated venture-capital firm investing in and coaching spin-outs from Kyoto University (and other national-university) research, via entrepreneur-in-residence and executive-coaching programmes designed to de-risk deep-tech companies before private capital steps in.
Official figures (Kyoto-iCAP's own portfolio page and fund announcements) show three sequential funds: "Innovation Kyoto 2016" (¥16.001 billion), "Innovation Kyoto 2021" (¥18.14 billion) and a third fund of roughly ¥20 billion, with institutional limited partners including Bank of Kyoto, Astellas Pharma, Shimadzu and SMBC Trust — cumulative assets under management around ¥54 billion. Independent reporting by Nikkei corroborates the Fund III target and LP roster. The official portfolio page lists 86 current portfolio companies (31 biotech/drug discovery, 25 machinery/materials/energy, 16 healthcare devices, 7 IoT/AI, 7 food/agriculture); portfolio company Chordia Therapeutics listed on the Tokyo Stock Exchange in June 2024.
Independent commentary notes Kyoto-iCAP can only invest in startups based on Kyoto University or other national-university research — a structural limit on deal flow — and that it operates specifically because Japan's broader VC culture is risk-averse and slow to fund deep-tech, meaning its existence addresses, rather than closes, that market gap.

Read the full analysis: https://www.kyoto-unicap.co.jp/en/